Roxadustat (Evrenzo™) is indicated for the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||01/09/2021|
|Rapid review completed||06/10/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that roxadustat not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.